Navigation Links
TetraLogic Pharmaceuticals Announces New Executives
Date:8/19/2013

dent, Global Branded Products, at Teva Pharmaceutical Industries Ltd. Prior to joining Teva, he was Chief Executive Officer of Cephalon, Inc., which was acquired by Teva for $8 billion in October 2011. Mr. Buchi joined Cephalon in 1991 and held various positions, including Chief Financial Officer and Chief Operating Officer, before becoming Cephalon's Chief Executive Officer in December 2010.  He graduated from Cornell University with a Bachelor of Arts degree in chemistry and received a Master of Management degree from the J.L. Kellogg Graduate School of Management at Northwestern University.  Mr. Buchi is a Certified Public Accountant.

Mr. Meyers was most recently Managing Director, Co-Head of Global Health Care Investment Banking at Deutsche Bank Securities Inc.  He joined Deutsche Bank in 2005 after serving six years with Credit Suisse First Boston LLC where he was a Managing Director in Health Care Investment Banking specializing in the biotechnology and pharmaceutical sectors.  Prior to that, he worked at Dillon, Read & Co., specializing in health care mergers and acquisitions.  Mr. Meyers earned a Bachelor of Science degree in finance from Boston College and a Master of Business Administration degree from Columbia Business School.

Dr. Russell is a hematologist/oncologist with more than 20 years of international pharmaceutical industry experience and leadership in the therapeutic areas of hematology/oncology, neurology, psychiatry, pain and inflammation, respiratory medicine, cardiovascular medicine and stem cell therapy. Dr. Russell was most recently Senior Vice President and Global Head, Research and Development, Global Branded Products for Teva Pharmaceuticals USA. She was appointed to this role upon Teva's acquisition of Cephalon, Inc., where she served as Executive Vice President and Chief Medical Officer from 2006 to 2011. She joined Cephalon in 2000 as Vice President, Worldwide Clinica
'/>"/>

SOURCE TetraLogic Pharmaceuticals
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. Savient Pharmaceuticals to Hold First Quarter 2012 Financial Results Conference Call on Wednesday, May 9, 2012
2. Auxilium Pharmaceuticals to Present at the Deutsche Bank 37th Annual Healthcare Conference
3. Nouveau Life Pharmaceuticals (HRID) Contracts with U.S. Manufacturer to Produce New Female Supplement
4. BioElectronics Survey Indicates a Five-Fold Superior Pain Relief Compared to OTC Pharmaceuticals
5. Icahn Issues Statement Regarding Amylin Pharmaceuticals
6. Almost 50 Percent of the Glaucoma Patient Population Remains Untreated, Signifying a Vast Market for Glaucoma Pharmaceuticals, Finds Frost & Sullivan
7. Omthera Pharmaceuticals Announces Positive Top-Line Results from Phase 3 EVOLVE Study
8. Onyx Pharmaceuticals Announces FDA Advisory Committee to Review Carfilzomib for the Treatment of Patients with Relapsed and Refractory Multiple Myeloma
9. Jazz Pharmaceuticals Announces First Quarter 2012 Financial Results Conference Call On May 8, 2012
10. Inovio Pharmaceuticals Granted U.S. Patent Protection for Synthetic Vaccine for Cervical Dysplasia and Cancer
11. Avanir Pharmaceuticals To Present at Three Conferences In May
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/22/2014)... Elekta (NSE:EKTAb) and Royal Philips ... Foundation Trust ( Manchester, UK ), a ... is to develop the clinical value of an integrated ... a system would, in principle, improve the practice of ... "The Christie was an essential participant in the ...
(Date:7/22/2014)... 2014 Sanofi Pasteur, the vaccines division of Sanofi ... that the first lots of Fluzone ® (Influenza Vaccine) ... by the U.S. Food and Drug Administration (FDA) for distribution. ... first of at least 65 million doses of seasonal influenza ... U.S. health care providers and pharmacies in August. ...
(Date:7/22/2014)... SAN DIEGO , July 22, 2014  Halozyme ... that it has resumed enrollment and dosing of patients ... PEGPH20 in patients with pancreatic cancer under the revised ... PEGPH20 is an investigational PEGylated form of Halozyme,s proprietary ... of tumors that accumulate hyaluronan. "Our ...
Breaking Medicine Technology:The Christie Hospital joins Elekta and Philips research consortium to develop MRI-guided radiation therapy system for cancer treatment 2The Christie Hospital joins Elekta and Philips research consortium to develop MRI-guided radiation therapy system for cancer treatment 3The Christie Hospital joins Elekta and Philips research consortium to develop MRI-guided radiation therapy system for cancer treatment 4Sanofi Pasteur Begins Shipping Seasonal Influenza Vaccine for Upcoming 2014-2015 Season in United States 2Sanofi Pasteur Begins Shipping Seasonal Influenza Vaccine for Upcoming 2014-2015 Season in United States 3Sanofi Pasteur Begins Shipping Seasonal Influenza Vaccine for Upcoming 2014-2015 Season in United States 4Sanofi Pasteur Begins Shipping Seasonal Influenza Vaccine for Upcoming 2014-2015 Season in United States 5Sanofi Pasteur Begins Shipping Seasonal Influenza Vaccine for Upcoming 2014-2015 Season in United States 6Sanofi Pasteur Begins Shipping Seasonal Influenza Vaccine for Upcoming 2014-2015 Season in United States 7Halozyme Resumes Patient Enrollment And Dosing In PEGPH20 Clinical Program In Pancreatic Cancer 2Halozyme Resumes Patient Enrollment And Dosing In PEGPH20 Clinical Program In Pancreatic Cancer 3
... ALL Study Group Presented Data at the 14th Congress ... in Patients with Minimal Residual Disease , , ... MITI ), a biopharmaceutical company developing novel, proprietary antibodies ... announced that the German Multicenter ALL Study Group (GMALL) ...
... 2 data sets to be released-- , ... clinical trials in patients with blepharospasm and cervical dystonia -- ... -- were presented at the Movement Disorder Society (MDS) 13th ... by Merz Pharmaceuticals, which plans to file a Biologic License ...
Cached Medicine Technology:Micromet's Blinatumomab Achieves Primary Endpoint in Phase 2 Study with Acute Lymphoblastic Leukemia Patients 2Micromet's Blinatumomab Achieves Primary Endpoint in Phase 2 Study with Acute Lymphoblastic Leukemia Patients 3Micromet's Blinatumomab Achieves Primary Endpoint in Phase 2 Study with Acute Lymphoblastic Leukemia Patients 4Micromet's Blinatumomab Achieves Primary Endpoint in Phase 2 Study with Acute Lymphoblastic Leukemia Patients 5Merz Pharmaceuticals Announces Results of Clinical Trials with NT-201(Botulinum neurotoxin type A free from complexing proteins) at Annual Movement Disorders Society Meeting 2Merz Pharmaceuticals Announces Results of Clinical Trials with NT-201(Botulinum neurotoxin type A free from complexing proteins) at Annual Movement Disorders Society Meeting 3Merz Pharmaceuticals Announces Results of Clinical Trials with NT-201(Botulinum neurotoxin type A free from complexing proteins) at Annual Movement Disorders Society Meeting 4
(Date:7/23/2014)... Hemodialysis equipment is the most widely used ... acute or chronic renal failure. , The Chinese hemodialysis ... European, American and Japanese enterprises. In 2013, the import ... growing demand for hemodialysis equipment in China, its import ... in 2009-2013. Germany, Sweden and Japan as the main ...
(Date:7/23/2014)... month of July, LunaDress, a well-known wedding dress manufacturer and ... hosting a couple of promotions on its website. Recently, the ... wedding dresses for the UK market . The fresh range ... are now offered with huge discounts, from 20 to 70 ... suppliers, LunaDress is always making full efforts to offer classy ...
(Date:7/23/2014)... 23, 2014 World Gardens Café, the ... healthy gourmet cuisine, received rave reviews last week when ... Mixer. Mixer attendees were amazed that healthy food could ... World Gardens Café, the premier provider of delicious and ... booth at Dave Linden’s LA’s Largest Mixer. Attendees who ...
(Date:7/23/2014)... 2014 Sanuvox has produced a ... of the company’s latest system designed for hospital ... System uses a primary and secondary unit to ... ‘C’ energy controlling (6 log reduction) drug-resistant microorganisms ... than 10 minutes in a standard patient hospital ...
(Date:7/23/2014)... Low enrollment and higher-than-expected administrative costs ... up with alternative means to becoming self-sustaining. Industry ... accomplish this in the July 17 issue of ... , “We never expected the operating budgets would ... an attorney at the law firm Venable LLP ...
Breaking Medicine News(10 mins):Health News:China Hemodialysis Equipment Market (Import & Export) Report 2013-2016 Now Available at ChinaMarketResearchReports.com 2Health News:China Hemodialysis Equipment Market (Import & Export) Report 2013-2016 Now Available at ChinaMarketResearchReports.com 3Health News:China Hemodialysis Equipment Market (Import & Export) Report 2013-2016 Now Available at ChinaMarketResearchReports.com 4Health News:LunaDress Continues To Enrich Product Line By Offering Short Summer Beach Wedding Dresses 2Health News:Healthy Food Gets Rave Reviews at LA’s Largest Mixer 2Health News:Sanuvox Produces ASEPTIX² Movie Showcasing the Feature Benefits of the Company’s Latest Flagship Hospital Surface Disinfection System 2Health News:Industry Observers Tell AIS They Predict Changes to Exchange User Fees, Platforms 2Health News:Industry Observers Tell AIS They Predict Changes to Exchange User Fees, Platforms 3
... from the University of North Carolina at Chapel Hill suggests that ... morning or later in the afternoon can influence the onset ... exposure to UV radiation in the morning increased the risk of ... Although mice and humans both reside on a 24-hour day, the ...
... Rockville, MD -- Physical activity may be what the ... developing glaucoma. According to a recently published scientific paper, ... long-term beneficial impact on low ocular perfusion pressure (OPP), ... the Investigative Ophthalmology & Visual Science journal ...
... LANSING, Mich. -- Despite the fact mental health problems ... combined, about two-thirds of mental health patients are cared ... Additionally, even larger numbers of other patients regularly ... A new five-year, $1 million grant allows Michigan State ...
... related macular degeneration (AMD) is the leading cause of ... identified several relatively common genetic variants which together predict ... number of persons without the disease also have these ... able to clearly show a specific rare mutation called ...
... study published today in the journal Nature Genetics ... Lieb, PhD, present experiments supporting a longstanding hypothesis that ... of the X chromosome. The finding provides clarity to ... with more information to interpret experiments involving genetic measurements ...
... FESC, from the University of Padua, Italy, explains, "To ... from all the different imaging modalities, not just Echo. ... is that we want to become more patient oriented, ... the most appropriate technology to address individual clinical questions." ...
Cached Medicine News:Health News:Morning UV exposure may be less damaging to the skin 2Health News:Physical fitness could have a positive effect on eye health 2Health News:Residency program focuses on overlooked mental health needs 2Health News:Researchers ID genetic mutation associated with high risk of age-related macular degeneration 2Health News:Study confirms males and females have at least 1 thing in common: Upregulating X 2Health News:Congress alert: EUROECHO and Other Imaging Modalities: New patient emphasis 2Health News:Congress alert: EUROECHO and Other Imaging Modalities: New patient emphasis 3
... Laboratories is a national reference laboratory and ... and development. ARUP offers an extensive test ... tests in clinical and anatomic pathology. Owned ... clients include more than half of the ...
... a national reference laboratory and a worldwide ... ARUP offers an extensive test menu of ... clinical and anatomic pathology. Owned by the ... more than half of the nation's university ...
... Laboratories is a national reference laboratory and ... and development. ARUP offers an extensive test ... tests in clinical and anatomic pathology. Owned ... clients include more than half of the ...
... Laboratories is a national reference laboratory and ... and development. ARUP offers an extensive test ... tests in clinical and anatomic pathology. Owned ... clients include more than half of the ...
Medicine Products: